These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Dry eye in LASIK patients. Azuma M; Yabuta C; Fraunfelder FW; Shearer TR BMC Res Notes; 2014 Jul; 7():420. PubMed ID: 24994125 [TBL] [Abstract][Full Text] [Related]
23. Novel liposome-based and in situ gelling artificial tear formulation for dry eye disease treatment. Acar D; Molina-Martínez IT; Gómez-Ballesteros M; Guzmán-Navarro M; Benítez-Del-Castillo JM; Herrero-Vanrell R Cont Lens Anterior Eye; 2018 Feb; 41(1):93-96. PubMed ID: 29223649 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of a Novel Artificial Tear in the Prevention and Treatment of Dry Eye in an Animal Model. She Y; Li J; Xiao B; Lu H; Liu H; Simmons PA; Vehige JG; Chen W J Ocul Pharmacol Ther; 2015 Nov; 31(9):525-30. PubMed ID: 26322539 [TBL] [Abstract][Full Text] [Related]
25. Study design and baseline findings from the progression of ocular findings (PROOF) natural history study of dry eye. McDonnell PJ; Pflugfelder SC; Stern ME; Hardten DR; Conway T; Villanueva L; Hollander DA BMC Ophthalmol; 2017 Dec; 17(1):265. PubMed ID: 29284427 [TBL] [Abstract][Full Text] [Related]
26. A Critical Appraisal of the Physicochemical Properties and Biological Effects of Artificial Tear Ingredients and Formulations. Weng J; Fink MK; Sharma A Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769079 [TBL] [Abstract][Full Text] [Related]
27. Clinical Outcomes of Fixed Versus As-Needed Use of Artificial Tears in Dry Eye Disease: A 6-Week, Observer-Masked Phase 4 Clinical Trial. Asbell P; Vingrys AJ; Tan J; Ogundele A; Downie LE; Jerkins G; Shettle L Invest Ophthalmol Vis Sci; 2018 May; 59(6):2275-2280. PubMed ID: 29715369 [TBL] [Abstract][Full Text] [Related]
28. Additive Effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops. Hwang HS; Sung YM; Lee WS; Kim EC Cornea; 2014 Sep; 33(9):935-41. PubMed ID: 25055152 [TBL] [Abstract][Full Text] [Related]
29. Efficacy, safety, and acceptability of a lipid-based artificial tear formulation: a randomized, controlled, multicenter clinical trial. Simmons PA; Carlisle-Wilcox C; Chen R; Liu H; Vehige JG Clin Ther; 2015 Apr; 37(4):858-68. PubMed ID: 25659956 [TBL] [Abstract][Full Text] [Related]
30. [Comparison of objective optical quality measured by double-pass aberrometry in patients with moderate dry eye: Normal saline vs. artificial tears: A pilot study]. Vandermeer G; Chamy Y; Pisella PJ J Fr Ophtalmol; 2018 Mar; 41(3):238-245. PubMed ID: 29573863 [TBL] [Abstract][Full Text] [Related]
31. Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study. Sacchetti M; Lambiase A; Schmidl D; Schmetterer L; Ferrari M; Mantelli F; Allegretti M; Garhoefer G Br J Ophthalmol; 2020 Jan; 104(1):127-135. PubMed ID: 30944103 [TBL] [Abstract][Full Text] [Related]
32. Serum eye drops for the treatment of ocular surface diseases: a systematic review and meta-analysis. Franchini M; Cruciani M; Mengoli C; Marano G; Capuzzo E; Pati I; Masiello F; Veropalumbo E; Pupella S; Vaglio S; Liumbruno GM Blood Transfus; 2019 May; 17(3):200-209. PubMed ID: 31246562 [TBL] [Abstract][Full Text] [Related]
33. Fluorescein-tear breakup time as an assessment of efficacy of tear replacement therapy in dry eye patients: a systematic review and meta-analysis. Doughty MJ Ocul Surf; 2014 Apr; 12(2):100-11. PubMed ID: 24725322 [TBL] [Abstract][Full Text] [Related]
34. An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops. Ousler GW; Michaelson C; Christensen MT Cornea; 2007 Sep; 26(8):949-52. PubMed ID: 17721294 [TBL] [Abstract][Full Text] [Related]
35. Influence of Artificial Tears on Keratometric Measurements in Cataract Patients. Röggla V; Leydolt C; Schartmüller D; Schwarzenbacher L; Meyer E; Abela-Formanek C; Menapace R Am J Ophthalmol; 2021 Jan; 221():1-8. PubMed ID: 32828877 [TBL] [Abstract][Full Text] [Related]
36. A review of the efficacy, safety and tolerability of Lacrycon Eberle Heitzmann M; Thumm D; Baudouin C J Fr Ophtalmol; 2019 Jun; 42(6):642-654. PubMed ID: 30929965 [TBL] [Abstract][Full Text] [Related]
37. Comparison of objective optical quality measured by double-pass aberrometry in patients with moderate dry eye: Normal saline vs. artificial tears: A pilot study. Vandermeer G; Chamy Y; Pisella PJ J Fr Ophtalmol; 2018 Feb; 41(2):e51-e57. PubMed ID: 29366588 [TBL] [Abstract][Full Text] [Related]
38. Relative costs of various preserved artificial tear solutions for the treatment of dry eye conditions. Enzenauer RW; Kao A; Williams T; Lambert RW Eye Contact Lens; 2003 Oct; 29(4):238-40. PubMed ID: 14555900 [TBL] [Abstract][Full Text] [Related]
39. Tear film thickness after treatment with artificial tears in patients with moderate dry eye disease. Schmidl D; Schmetterer L; Witkowska KJ; Unterhuber A; dos Santos VA; Kaya S; Nepp J; Baar C; Rosner P; Werkmeister RM; Garhofer G Cornea; 2015 Apr; 34(4):421-6. PubMed ID: 25651494 [TBL] [Abstract][Full Text] [Related]
40. Comparison of Autologous Serum Versus Preservative Free Artificial Tear in Patients with Dry Eyes Due to Systemic Isotretinoin Therapy. Yılmaz U; Küçük E; Koç Ç; Gökler E Curr Eye Res; 2017 Jun; 42(6):827-831. PubMed ID: 28139163 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]